Document_and_Entity_Informatio
Document and Entity Information | 9 Months Ended | |
Sep. 30, 2013 | Nov. 08, 2013 | |
Document Document And Entity Information [Line Items] | ' | ' |
Entity Registrant Name | 'ARCA Biopharma, Inc. | ' |
Entity Central Index Key | '0000907654 | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Document Fiscal Year Focus | '2013 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 15,675,562 |
Consolidated_Balance_Sheets_un
Consolidated Balance Sheets (unaudited) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $18,632 | $2,920 |
Other current assets | 379 | 125 |
Total current assets | 19,011 | 3,045 |
Property and equipment, net | 27 | 23 |
Other assets | 100 | 144 |
Total assets | 19,138 | 3,212 |
Current liabilities: | ' | ' |
Accounts payable | 447 | 65 |
Accrued compensation and employee benefits | 75 | 103 |
Accrued expenses and other liabilities | 247 | 121 |
Deferred rent, current portion | ' | 16 |
Total current liabilities | 769 | 305 |
Total liabilities | 769 | 305 |
Commitments and contingencies | ' | ' |
Stockholders’ equity: | ' | ' |
Series A convertible preferred stock, $0.001 par value; 135,000 shares authorized; 24,902 shares issued and outstanding at September 30, 2013; no shares authorized, issued and outstanding at December 31, 2012 | ' | ' |
Common stock, $0.001 par value; 100 million shares authorized; 13,195,362 shares issued and outstanding at September 30, 2013; 2,660,315 shares issued and outstanding at December 31, 2012. | 13 | 3 |
Additional paid-in capital | 90,343 | 70,898 |
Deficit accumulated during the development stage | -71,987 | -67,994 |
Total stockholders’ equity | 18,369 | 2,907 |
Total liabilities and stockholders’ equity | $19,138 | $3,212 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (unaudited) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Statement Consolidated Balance Sheets Parenthetical Unaudited [Line Items] | ' | ' |
Common stock, par value | $0.00 | $0.00 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 13,195,362 | 2,660,315 |
Common stock, shares outstanding | 13,195,362 | 2,660,315 |
Series A | ' | ' |
Statement Consolidated Balance Sheets Parenthetical Unaudited [Line Items] | ' | ' |
Convertible preferred stock, par value | $0.00 | ' |
Convertible preferred stock, shares authorized | 135,000 | 0 |
Convertible preferred stock, issued | 24,902 | 0 |
Convertible preferred stock, outstanding | 24,902 | 0 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations and Comprehensive Loss (unaudited) (USD $) | 3 Months Ended | 9 Months Ended | 141 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 |
Costs and expenses: | ' | ' | ' | ' | ' |
Research and development | $714 | $156 | $1,141 | $901 | $43,818 |
Selling, general and administrative | 1,011 | 772 | 2,852 | 2,579 | 45,435 |
Merger transaction costs | ' | ' | ' | ' | 5,470 |
Restructuring expense, net | ' | ' | ' | ' | 2,413 |
Loss on impairment of in-process research and development | ' | ' | ' | ' | 6,000 |
Total costs and expenses | 1,725 | 928 | 3,993 | 3,480 | 103,136 |
Loss from operations | -1,725 | -928 | -3,993 | -3,480 | -103,136 |
Gain on assignment of patent rights | ' | ' | ' | ' | 2,000 |
Gain on bargain purchase | ' | ' | ' | ' | 25,282 |
Interest and other income | 2 | 2 | 3 | 3 | 2,031 |
Interest and other expense | ' | -1 | -3 | -3 | -445 |
Loss before income taxes | -1,723 | -927 | -3,993 | -3,480 | -74,268 |
Benefit from income taxes | ' | ' | ' | ' | 2,281 |
Net loss and comprehensive loss | -1,723 | -927 | -3,993 | -3,480 | -71,987 |
Less: Accretion of redeemable convertible preferred stock | ' | ' | ' | ' | -245 |
Less: Deemed preferred stock dividend | ' | ' | -2,026 | ' | -2,807 |
Net loss attributable to common stockholders | ($1,723) | ($927) | ($6,019) | ($3,480) | ($75,039) |
Net loss attributable to common stockholders per share: | ' | ' | ' | ' | ' |
Basic and diluted | ($0.16) | ($0.41) | ($0.96) | ($1.65) | ' |
Weighted average shares outstanding: | ' | ' | ' | ' | ' |
Basic and diluted | 10,832,516 | 2,283,736 | 6,299,828 | 2,113,679 | ' |
Consolidated_Statements_of_Pre
Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (USD $) | Total | Cash, Net of Offering Costs | Issuance for Notes Payable and Related Accrued Interest on January 3, 2005 | Issuance for Intellectual Property License Rights on October 14, 2005 | Issuance for Notes Payable and Related Accrued Interest on October 14, 2005 | Issuance for Intellectual Property License Rights on February 21, 2006 | Issuance for Intellectual Property License Rights on February 22, 2006 | Issuance for Intellectual Property License Rights on June 23, 2006 | Issuance for Intellectual Property License Rights on November 7, 2006 | Accretion of Series A | Accretion of Series B | Issuance for Intellectual Property License Rights on January 18, 2007 | Issuance for Intellectual Property License Rights on June 30, 2007 | Issuance of Common Stock for Commercial License Rights, on July 19, 2007 | Issuance of Shares to Executive Subject to Repurchase | Common Conversion | Notes and Related Accrued Interest | Series A | Series A | Series A | Series A | Series A | Series A | Series A | Series A | Series A | Series B | Series B | Series B | Series B | Series B | Series B | Series B | Series B | Series A Convertible Preferred Stock | Series A Convertible Preferred Stock | Series A Convertible Preferred Stock | Series A Convertible Preferred Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Additional Paid-in Capital | Deficit Accumulated During Development Stage | Deficit Accumulated During Development Stage | Deficit Accumulated During Development Stage | Deficit Accumulated During Development Stage |
In Thousands, except Share data | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | Issuance of Series A on February 22, 2006 | Third Issuance For Notes Payable And Related Accrued Interest | Issuance for Intellectual Property License Rights on November 7, 2006 | Series A offering costs | Accretion of Series A | Issuance of Common Stock for Commercial License Rights, on July 19, 2007 | Issuance of Shares to Executive Subject to Repurchase | Common Conversion | USD ($) | Issuance for Intellectual Property License Rights on November 7, 2006 | Third Issuance Of Series B Convertible Redeemable Preferred Stock | Issuance for Series B on December 28, 2007 | Accretion of Series B | Issuance of Common Stock for Commercial License Rights, on July 19, 2007 | Issuance of Shares to Executive Subject to Repurchase | Common Conversion | USD ($) | Issuance for Intellectual Property License Rights on November 7, 2006 | Issuance of Common Stock for Commercial License Rights, on July 19, 2007 | Issuance of Shares to Executive Subject to Repurchase | USD ($) | Cash, Net of Offering Costs | Issuance for Notes Payable and Related Accrued Interest on January 3, 2005 | Issuance for Intellectual Property License Rights on October 14, 2005 | Issuance for Notes Payable and Related Accrued Interest on October 14, 2005 | Issuance for Intellectual Property License Rights on February 21, 2006 | Issuance for Intellectual Property License Rights on February 22, 2006 | Issuance for Intellectual Property License Rights on June 23, 2006 | Issuance for Intellectual Property License Rights on November 7, 2006 | Issuance for Intellectual Property License Rights on January 18, 2007 | Issuance for Intellectual Property License Rights on June 30, 2007 | Issuance of Common Stock for Commercial License Rights, on July 19, 2007 | Issuance of Shares to Executive Subject to Repurchase | Common Conversion | Notes and Related Accrued Interest | USD ($) | Cash, Net of Offering Costs | Issuance for Notes Payable and Related Accrued Interest on January 3, 2005 | Issuance for Intellectual Property License Rights on October 14, 2005 | Issuance for Notes Payable and Related Accrued Interest on October 14, 2005 | Issuance for Intellectual Property License Rights on February 21, 2006 | Issuance for Intellectual Property License Rights on February 22, 2006 | Issuance for Intellectual Property License Rights on June 23, 2006 | Issuance for Intellectual Property License Rights on November 7, 2006 | Accretion of Series A | Accretion of Series B | Issuance for Intellectual Property License Rights on January 18, 2007 | Issuance for Intellectual Property License Rights on June 30, 2007 | Issuance of Common Stock for Commercial License Rights, on July 19, 2007 | Issuance of Shares to Executive Subject to Repurchase | Common Conversion | Notes and Related Accrued Interest | USD ($) | Issuance for Intellectual Property License Rights on November 7, 2006 | Issuance of Common Stock for Commercial License Rights, on July 19, 2007 | Issuance of Shares to Executive Subject to Repurchase |
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||||||||||||||||||||||||||||||||
Beginning Balance, value at Dec. 17, 2001 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Beginning Balance, shares at Dec. 17, 2001 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,588 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -116 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -116 | ' | ' | ' |
Ending Balance, value at Dec. 31, 2003 | -115 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -116 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2003 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,588 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | 7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19,720 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -511 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -511 | ' | ' | ' |
Ending Balance, value at Dec. 31, 2004 | -619 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -627 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2004 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 22,308 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | 1 | ' | 1 | 44 | 1,354 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | 1 | 44 | 1,354 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,922 | 2,978 | 903 | 31,095 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -1,459 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,459 | ' | ' | ' |
Ending Balance, value at Dec. 31, 2005 | -678 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,408 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,086 | ' | ' | ' |
Beginning Balance, shares at Dec. 31, 2005 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 60,206 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | ' | ' | ' | ' | ' | 75 | 60 | 15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,316 | ' | ' | 5,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 75 | 60 | 15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,727,354 | ' | ' | 3,074,086 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17,372 | 13,907 | 2,505 | 38 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -5,241 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -5,241 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 684 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 420,817 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, value | 3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,019 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Offering costs | -17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17 | ' | ' | ' | -98 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 39 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 39 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Dec. 31, 2006 | -5,744 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14,919 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,583 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -7,327 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2006 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,222,257 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 102,047 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 13 | 7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,000 | 9,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 13 | 7 | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,688,902 | 2,766,677 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,303 | 642 | 2,783 | 13,915 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -13,994 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -13,994 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, value | 16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,227 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Offering costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | -19 | -18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19 | ' | ' | ' | -147 | ' | ' | ' | 18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -19 | -18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Dec. 31, 2007 | -19,689 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14,938 | ' | ' | ' | ' | ' | ' | ' | ' | 17,871 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,632 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -21,321 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2007 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,222,257 | ' | ' | ' | ' | ' | ' | ' | ' | 6,455,579 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 122,917 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -19,431 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -19,431 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, value | 54 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 54 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 36,154 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Offering costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | -20 | -36 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20 | ' | ' | ' | ' | ' | ' | ' | 36 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -20 | -36 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 545 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 545 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated fair value of warrants issued in connection with convertible notes payable | 399 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 399 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Dec. 31, 2008 | -38,178 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 14,958 | ' | ' | ' | ' | ' | ' | ' | ' | 17,907 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,574 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -40,752 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2008 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,222,257 | ' | ' | ' | ' | ' | ' | ' | ' | 6,455,579 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 159,071 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -9,138 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -9,138 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, value | 114 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 114 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,521 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Offering costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | -42 | -93 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 42 | ' | ' | ' | ' | ' | ' | ' | 93 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -42 | -93 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 845 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 845 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjustment for fractional shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -102 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deemed preferred stock dividend for additional common shares issuable under anti-dilution provision | -781 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 781 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -781 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of preferred stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33,781 | ' | ' | ' | ' | ' | ' | ' | ' | ' | -15,000 | ' | ' | ' | ' | ' | ' | ' | -18,781 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33,780 | ' | ' | ' | ' | ' |
Conversion of preferred stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -9,222,257 | ' | ' | ' | ' | ' | ' | ' | -6,455,579 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 507,123 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted stock release from restriction | 75 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 75 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of convertible notes and related accrued interest | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,501 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,501 | ' | ' | ' | ' |
Shares of common stock purchased | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 145,465 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of warrants for preferred stock | 36 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 36 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Merger with Nuvelo, Inc., value | 11,913 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 11,913 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Merger with Nuvelo, Inc., shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 447,826 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units, value | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 177 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated fair value of warrants issued in connection with lease termination | 377 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 377 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Dec. 31, 2009 | 7,412 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 57,301 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -49,890 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2009 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,270,074 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | 7,182 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,182 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 194,100 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -8,420 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -8,420 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, value | 139 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 139 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,248 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 458 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 458 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Dec. 31, 2010 | 6,771 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 65,080 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -58,310 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2010 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,472,422 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | ' | 4,017 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,016 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 557,890 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -5,364 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -5,364 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 188 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 308 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 308 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Dec. 31, 2011 | 5,732 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 69,404 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -63,674 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2011 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,030,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | ' | 1,189 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,188 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 629,815 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -4,320 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -4,320 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 306 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 306 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Dec. 31, 2012 | 2,907 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 70,898 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -67,994 | ' | ' | ' |
Ending Balance, shares at Dec. 31, 2012 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,660,315 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, value | 1,421 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,421 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock for cash, net of offering costs, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 521,066 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | -3,993 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -3,993 | ' | ' | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based compensation | 125 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 125 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Adjustment for fractional shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -64 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of preferred stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of preferred stock, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -100,098 | ' | ' | ' | 10,009,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock warrants, for cash, value | 12 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of common stock upon exercise of stock warrants, for cash, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,245 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of Series A convertible preferred stock, net of offering costs, Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 125,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of Series A convertible preferred stock, net of offering costs, Value | 17,917 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17,917 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deemed preferred stock dividend for beneficial conversion feature | 2,026 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,026 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Less: Deemed preferred stock dividend | -2,026 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,026 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Costs of issuance of common stock and conversion of preferred stock to common stock | -20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending Balance, value at Sep. 30, 2013 | $18,369 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $90,343 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($71,987) | ' | ' | ' |
Ending Balance, shares at Sep. 30, 2013 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Consolidated_Statements_of_Pre1
Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (Parenthetical) (USD $) | Jan. 03, 2005 | Sep. 30, 2004 | Dec. 31, 2002 | Jan. 03, 2005 | Oct. 14, 2005 | Feb. 21, 2006 | Feb. 22, 2006 | Jun. 23, 2006 | Nov. 07, 2006 | Jan. 18, 2007 | Jun. 30, 2007 | Feb. 22, 2006 | Feb. 22, 2006 | Dec. 08, 2006 | 31-May-07 | Dec. 28, 2007 |
Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Common Stock | Series A | Series A | Series A | Series B | Series B | |
Cash, Net of Offering Costs | Cash, Net of Offering Costs | Cash, Net of Offering Costs | Issuance for Notes Payable and Related Accrued Interest on January 3, 2005 | Issuance for Intellectual Property License Rights on October 14, 2005 | Issuance for Intellectual Property License Rights on February 21, 2006 | Issuance for Intellectual Property License Rights on February 22, 2006 | Issuance for Intellectual Property License Rights on June 23, 2006 | Fifth Issuance Of Stock For Intellectual Property License Rights | Sixth Issuance Of Stock For Intellectual Property License Rights | Seventh Issuance Of Stock For Intellectual Property License Rights | Issuance of Series A on February 22, 2006 | Third Issuance For Notes Payable And Related Accrued Interest | Second Issuance Of Series Convertible Redeemable Preferred Stock | Third Issuance Of Series B Convertible Redeemable Preferred Stock | Issuance for Series B on December 28, 2007 | |
Common stock market price per share | $0.36 | $0.36 | $0.36 | $0.36 | $48.84 | $4.32 | $4.32 | $5.40 | $5.40 | $10.08 | $10.80 | ' | ' | ' | ' | ' |
Preferred stock, par value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.63 | $1.63 | $1.63 | $2.44 | $3.25 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (unaudited) (USD $) | 9 Months Ended | 141 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 |
Cash flows used in operating activities: | ' | ' | ' |
Net loss | ($3,993) | ($3,480) | ($71,987) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | ' |
Gain on patent rights assignment | ' | ' | -2,000 |
Gain on bargain purchase | ' | ' | -25,282 |
Depreciation and amortization | 24 | 34 | 1,804 |
Non-cash interest expense | ' | ' | 211 |
Share-based compensation | 125 | 243 | 2,713 |
Issuance of warrants for lease termination | ' | ' | 377 |
Accretion of liabilities | ' | ' | 152 |
Impairment of property and equipment | ' | ' | 125 |
Loss on impairment of in-process research and development | ' | ' | 6,000 |
Write-off of deferred tax liability | ' | ' | -2,281 |
Gain on marketable securities available for sale | ' | ' | -263 |
(Gain) loss from disposal of property and equipment | ' | ' | 83 |
Other, net | ' | ' | 267 |
Change in operating assets and liabilities (net of amounts acquired): | ' | ' | ' |
Other current assets | -80 | 219 | 2,740 |
Other assets | 44 | 60 | 7,370 |
Accounts payable | 382 | -141 | -1,743 |
Accrued expenses and other liabilities | 98 | -318 | -19,123 |
Deferred rent | -16 | -25 | ' |
Net cash used in operating activities | -3,416 | -3,408 | -100,837 |
Cash flows (used in) provided by investing activities: | ' | ' | ' |
Cash received from Merger | ' | ' | 30,392 |
Payment of deferred transaction costs | ' | ' | -1,186 |
Purchase of property and equipment | -28 | -1 | -1,907 |
Proceeds from sale of marketable securities | ' | ' | 15,369 |
Proceeds from sale of property and equipment | ' | ' | 358 |
Proceeds from patent rights assignment | ' | ' | 2,000 |
Net cash (used in) provided by investing activities | -28 | -1 | 45,026 |
Cash flows provided by (used in) financing activities: | ' | ' | ' |
Proceeds from issuance of convertible notes payable and related warrants for common stock | ' | ' | 10,841 |
Proceeds from issuance of bank note payable | ' | ' | 4,000 |
Proceeds from stock subject to repurchase | ' | ' | 38 |
Proceeds from the issuance of preferred stock | 20,000 | ' | 52,316 |
Payment of offering costs | 20 | ' | ' |
Proceeds from the issuance of common stock | 1,741 | 953 | 15,850 |
Repayment of principal on bank note payable | ' | ' | -4,000 |
Repayment of principal on convertible notes payables | ' | ' | -105 |
Repayment of principal on vendor finance agreement | -174 | -134 | -454 |
Net cash provided by (used in) financing activities | 19,156 | 547 | 74,443 |
Net increase (decrease) in cash and cash equivalents | 15,712 | -2,862 | 18,632 |
Cash and cash equivalents, beginning of period | 2,920 | 5,943 | ' |
Cash and cash equivalents, end of period | 18,632 | 3,081 | 18,632 |
Supplemental cash flow information: | ' | ' | ' |
Interest paid | 3 | 3 | 118 |
Supplemental disclosure of noncash investing and financing transactions: | ' | ' | ' |
Accrued interest on notes payable converted to equity | ' | ' | 163 |
Warrant issued in connection with credit facility | ' | ' | 111 |
Accrued deferred transaction costs | ' | ' | 482 |
Vendor finance agreement | ' | ' | ' |
Preferred Stock | ' | ' | ' |
Cash flows provided by (used in) financing activities: | ' | ' | ' |
Payment of offering costs | -2,083 | ' | -2,329 |
Common Stock | ' | ' | ' |
Cash flows provided by (used in) financing activities: | ' | ' | ' |
Payment of offering costs | ($328) | ($272) | ($1,714) |
The_Company_and_Summary_of_Sig
The Company and Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2013 | |
The Company and Summary of Significant Accounting Policies | ' |
(1) The Company and Summary of Significant Accounting Policies | |
Description of Business | |
ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado and is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, Gencaro™ (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator that ARCA plans to evaluate in a new clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro’s pharmacology and may predict patient response to the drug. | |
The Company plans to test this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, suggest that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is planned as a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients recently diagnosed with persistent AF and having beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF or all-cause mortality. | |
ARCA has created an adaptive design for GENETIC-AF which it plans to initiate with a Phase 2B study in approximately 200 HFREF patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze selected data from the Phase 2B portion of the trial and recommend whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of selected trial data after 200 patients have been enrolled and have completed 24 weeks of follow-up, the period for measuring the trial’s primary end-point. The interim analysis will focus on available data regarding AF event rates, AF burden, and safety. Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and that the data indicates potential for achieving statistical significance for the Phase 3 endpoint, then the DSMB may recommend the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial’s clinical steering committee and the DSMB, will make the final determination on the trial’s development steps. The Company believes the Phase 2B portion of the study would take approximately two and one-half years to complete from the time the first patient is enrolled until the planned DSMB interim analysis of data from the initial 200 patients. | |
The Company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing, which the Company believes may provide market exclusivity for these uses of Gencaro into at least 2026 in the U.S. and into 2025 in Europe. In addition, the Company believes that if Gencaro is approved, a Gencaro patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for Gencaro into 2029 or 2030 in the U.S. and Europe. | |
To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional funding through public or private equity transactions or a strategic combination or partnership. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. | |
Development Stage Risks, Liquidity and Going Concern | |
The Company is in the development stage and devotes substantially all of its efforts towards obtaining regulatory approval for Gencaro and raising capital necessary to fund its operations. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of common and preferred stock, as well as through the business combination with Nuvelo, Inc, or Nuvelo. | |
Since ARCA was founded on December 17, 2001, or Inception, the Company has incurred substantial losses and negative cash flows from operations. Since Inception, the Company incurred a loss from operations of $103.1 million and had negative cash flows from operations of $100.8 million. | |
To support the continued development of Gencaro, the Company completed a public equity offering in June 2013 to initiate the Phase 2B/3 GENETIC-AF trial and fund ongoing operations. In light of the substantial additional time and costs associated with the development of Gencaro, the Company will need to raise a significant amount of capital on acceptable terms to finance the completion of GENETIC-AF and the Company’s ongoing operations. The Company currently believes its cash and cash equivalents balance as of September 30, 2013 will be sufficient to fund its operations through at least 2014. However, changing circumstances may cause the Company to consume capital significantly faster or slower than is currently anticipated. These estimates are based upon assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than currently projected. | |
The Company’s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: | |
the costs and timing for the planned GENETIC-AF clinical trial ; | |
the market price of the Company’s stock and the availability and cost of additional equity or debt capital; | |
the Company’s ability to retain the listing of its common stock on the Nasdaq Capital Market; | |
general economic and industry conditions affecting the availability and cost of capital; | |
the Company’s ability to control costs associated with its operations; | |
the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and | |
the terms and conditions of the Company’s existing collaborative and licensing agreements. | |
The sale of additional equity or convertible debt securities would likely result in additional dilution to the Company’s existing stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company’s capital stock and could contain covenants that would restrict the Company’s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. | |
Reverse Stock Split | |
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. | |
Basis of Presentation | |
The accompanying unaudited consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of results expected for the full year ending December 31, 2013. The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing Gencaro, and raising capital. Accordingly, the Company continues to be considered in the development stage at September 30, 2013. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, as amended. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values. | |
Concentrations of Credit Risk | |
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. | |
Accrued Expenses | |
As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company’s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. |
Loss_Per_Share
Loss Per Share | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Loss Per Share | ' | ||||||||||||||||||||
(2) Loss Per Share | |||||||||||||||||||||
The Company calculates basic loss per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. In the three and nine month periods ended September 30, 2013, the calculation of net loss attributable to common stockholders includes the effect of the deemed dividend to Series A Preferred Stock purchasers (see Note 7). | |||||||||||||||||||||
Diluted loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company’s potentially dilutive shares include Series A Convertible Preferred Stock, stock options and warrants for common stock. | |||||||||||||||||||||
A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: | |||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
(In thousands, except shares and per share data) | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Net loss | $ | (1,723 | ) | $ | (927 | ) | $ | (3,993 | ) | $ | (3,480 | ) | |||||||||
Less: Series A Preferred Stock deemed dividend | — | — | (2,026 | ) | — | ||||||||||||||||
Net loss available to common shareholders | $ | (1,723 | ) | $ | (927 | ) | $ | (6,019 | ) | $ | (3,480 | ) | |||||||||
Weighted average shares of common stock outstanding | 10,835,299 | 2,286,519 | 6,302,611 | 2,116,462 | |||||||||||||||||
Less: Weighted-average shares of unvested common stock | (2,783 | ) | (2,783 | ) | (2,783 | ) | (2,783 | ) | |||||||||||||
Total weighted-average shares used in computing net loss per share attributed to common stockholders | 10,832,516 | 2,283,736 | 6,299,828 | 2,113,679 | |||||||||||||||||
Basic and diluted loss per share | $ | (0.16 | ) | $ | (.41 | ) | $ | (0.96 | ) | $ | (1.65 | ) | |||||||||
Potentially dilutive securities representing 13.1 million and 0.8 million weighted average shares of common stock were excluded for the three months ended September 30, 2013 and 2012, respectively, and potentially dilutive securities representing 6.7 million and 0.7 million weighted average shares of common stock were excluded for the nine months ended September 30, 2013 and 2012, respectively, because including them would have an anti-dilutive effect on net loss per share. |
Merger_with_Nuvelo_Inc_on_Janu
Merger with Nuvelo, Inc. on January 27, 2009 | 9 Months Ended |
Sep. 30, 2013 | |
Merger with Nuvelo, Inc. on January 27, 2009 | ' |
(3) Merger with Nuvelo, Inc. on January 27, 2009 | |
On January 27, 2009, ARCA Colorado, Inc. (ARCA Colorado) completed the Merger with Nuvelo in accordance with the terms of the Merger Agreement, in which a wholly-owned subsidiary of Nuvelo merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc., and its common stock began trading on the Nasdaq Global Market under the symbol “ABIO” on January 28, 2009. On March 7, 2011, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market. | |
The Merger was treated as a reverse merger and accounted for as a business combination using the acquisition method of accounting in accordance with ASC 805. For accounting purposes, ARCA Colorado was considered to have acquired Nuvelo in the Merger, as the stockholders of ARCA Colorado prior to the Merger had a controlling interest in the combined company and the Company’s management is the former management of ARCA Colorado. The results of operations and cash flows include the activities of Nuvelo since the date of the Merger. Pursuant to the rules and regulations of the United States Securities and Exchange Commission, or the SEC, the historical financial statements of ARCA Colorado replaced the historical financial statements of Nuvelo, and the disclosures in this report relating to the pre-Merger business of the Company, unless noted as being the business of Nuvelo prior to the Merger, pertain to the business of ARCA Colorado prior to the Merger. | |
The estimated total acquisition consideration of $11.9 million to acquire Nuvelo was based on the market capitalization of Nuvelo as of January 27, 2009 and the estimated fair values of its vested stock options and warrants outstanding on that date, as this was deemed the most reliable measure of the consideration effectively transferred to acquire Nuvelo on that date. The Company estimated the net assets acquired in the Merger to be $37.2 million, including $45.5 million of cash, cash equivalents and marketable securities. In accordance with ASC 805, any excess of fair value of net assets acquired in a business combination over the acquisition consideration results in a gain on bargain purchase, and as a result, the Company recorded a gain on bargain purchase of $25.3 million. |
Fair_Value_Disclosures
Fair Value Disclosures | 9 Months Ended |
Sep. 30, 2013 | |
Fair Value Disclosures | ' |
(4) Fair Value Disclosures | |
As of September 30, 2013, the Company had $18.6 million of cash equivalents consisting of money market funds with maturities of 90 days or less. The Company has the ability to liquidate these investments without restriction. The Company determines fair value for these money market funds and equity securities with Level 1 inputs through quoted market prices. There were no transfers of assets between fair value hierarchy levels during the three or nine month period ended September 30, 2013. | |
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: | |
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities | |
Level 2—Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability | |
Level 3—Unobservable inputs for the asset or liability | |
Fair Value of Other Financial Instruments | |
The carrying amount of other financial instruments, including cash, accounts payable, and short-term notes payable approximated fair value due to their short maturities. |
Property_and_Equipment
Property and Equipment | 9 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Property and Equipment | ' | ||||||||||||
(5) Property and Equipment | |||||||||||||
Property and equipment consist of the following (in thousands): | |||||||||||||
Estimated Life | September 30, | December 31, | |||||||||||
2013 | 2012 | ||||||||||||
Computer equipment | 3 years | $ | 97 | $ | 104 | ||||||||
Lab equipment | 5 years | 142 | 142 | ||||||||||
Furniture and fixtures | 5 years | 86 | 93 | ||||||||||
Computer software | 3 years | 176 | 176 | ||||||||||
Leasehold improvements | Lesser of useful life or life of the lease | 8 | 18 | ||||||||||
509 | 533 | ||||||||||||
Less accumulated depreciation and amortization | (482 | ) | (510 | ) | |||||||||
$ | 27 | $ | 23 | ||||||||||
For the nine months ended September 30, 2013 and 2012, and for the period from Inception through September 30, 2013, depreciation and amortization expense was $24,000, $34,000, and $1.8 million respectively. |
Commitments_and_Contingencies
Commitments and Contingencies | 9 Months Ended | ||||
Sep. 30, 2013 | |||||
Commitments and Contingencies | ' | ||||
(6) Commitments and Contingencies | |||||
The Company has or is subject to the following commitments and contingencies: | |||||
Employment Agreements | |||||
The Company maintains employment agreements with several executive employees. Most of these agreements provide for payments to be made under certain conditions related to a change in control of the Company and entitle the employee to wages and certain benefits payments not exceeding one calendar year from the date of termination without cause or by the employee for good reason. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee. | |||||
Operating Lease | |||||
On February 8, 2008, the Company entered into a lease agreement for approximately 15,000 square feet of newly constructed office facilities in Broomfield, Colorado. The office location served as the Company’s primary business office. In June 2011, the Company and its landlord amended the lease mutually agreeing for the Company to relocate to another suite, comprising approximately 4,500 square feet, within the same building. The original five year term of the Lease remained unchanged. The Company’s facility lease which would have originally expired in June 2013 was extended by a letter of extension through September 30 2013. | |||||
Rent expense under this lease for the nine months ended September 30, 2013 and 2012 was $44,000 and $36,000, respectively, and was $559,000 from Inception through September 30, 2013. | |||||
Effective August, 1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado that has served as the Company’s primary business office since October 1, 2013. Below is a summary of the future minimum lease payments committed for the Company’s facility in Westminster, Colorado as of September 30, 2013: | |||||
2013 | $ | 19,000 | |||
2014 | 78,000 | ||||
2015 | 81,000 | ||||
2016 | 62,000 | ||||
Total future minimum lease payments | $ | 240,000 | |||
Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC | |||||
Under the terms of its strategic license agreement with CPEC, a licensing subsidiary of Indevus Pharmaceuticals Inc. (a wholly owned subsidiary of Endo Pharmaceuticals), holding ownership rights to certain clinical trial data of Gencaro, the Company will incur milestone and royalty obligations upon the occurrence of certain events. In August 2008, the Company paid CPEC a milestone payment of $500,000 based on the July 31, 2008 submission of its NDA to the FDA. If the FDA grants marketing approval for Gencaro, the agreement provides that the Company will owe CPEC another milestone payment of $8.0 million within six months after FDA approval. The agreement also states that the Company has the obligation to make milestone payments of up to $5.0 million in the aggregate upon regulatory marketing approval in Europe and Japan. The agreement states that the Company’s royalty obligation ranges from 12.5% to 25% of revenue from the related product based on achievement of specified product sales levels, including a 5% royalty that CPEC is obligated to pay under its original license agreement for Gencaro. The Company has the right to buy down the royalties to a range of 12.5% to 17% by making a payment to CPEC within six months of regulatory approval. |
Equity_Financings_and_Warrants
Equity Financings and Warrants | 9 Months Ended |
Sep. 30, 2013 | |
Equity Financings and Warrants | ' |
(7) Equity Financings and Warrants | |
Private Investment in Public Equity (PIPE) Transaction | |
On January 22, 2013, the Company entered into a Subscription Agreement (the “Purchase Agreement”) with various accredited investors and its Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the Purchase Agreement, the Company sold an aggregate of 356,430 shares of its common stock and warrants to purchase up to 249,501 additional shares of its common stock for aggregate gross proceeds of approximately $1 million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $805,000, and the private placement closed on January 25, 2013. | |
The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.70 shares of common stock. The purchase price for each unit was $2.81. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share, equal to 100% of the closing bid price of ARCA’s common stock on the Nasdaq Capital Market on January 22, 2013. | |
The Company filed a registration statement for the resale of the shares underlying the units sold in these private placements. That registration statement was declared effective by the Securities and Exchange Commission on February 14, 2013. | |
In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a “variable rate transaction,” which means a transaction in which the Company issues or sells any convertible securities either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. In addition, the Company agreed that, subject to certain exceptions, if it issues securities within one year following the closing of the offering, each investor would have the right to purchase its pro rata share of a specified portion of the securities in the future offering on the same terms, conditions and price provided for in the proposed issuance of securities. | |
Registered Direct Offering | |
On January 31, 2013, the Company entered into a subscription agreement with certain institutional investors (the “Investors”) in connection with its Registered Direct public offering (the “Offering”), pursuant to which the Company sold an aggregate of 164,636 shares of its common stock and warrants to purchase up to 65,855 additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $730,000, before deducting placement agent fee and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $616,000, and the Offering closed on February 4, 2013. | |
The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.40 shares of common stock. The purchase price for each unit was $4.43. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share, equal to the closing bid price of ARCA’s common stock on the Nasdaq Capital Market on January 31, 2013. The Offering was effected as a takedown off the Company’s S-3 Registration Statement, which became effective on April 4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February 1, 2013. The warrant agreements provide for settlement of the warrants in unregistered shares should an effective registration statement or current prospectus not be in place at the time a warrant is exercised. | |
Public Offering | |
On June 4, 2013, the Company sold shares of its Series A Convertible Preferred Stock (Preferred Stock) and warrants to purchase common stock in a public offering for aggregate gross proceeds of $20.0 million. The Company issued 125,000 shares of Preferred Stock and warrants to purchase up to 6,250,000 shares of common stock at a purchase price of $160 per share of Preferred Stock. The net proceeds, after deducting placement agent fees and other offering expenses payable by the Company, were approximately $17.9 million. ARCA’s Director and Chief Executive Officer participated in the offering, purchasing 781 shares of Preferred Stock and warrants to purchase 39,050 shares of common stock. | |
Each share of Preferred Stock is initially convertible into 100 shares of the Company’s common stock at any time at the option of the holder; provided, that the holder will be prohibited from converting to the extent that, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding. Each share of Preferred Stock has a liquidation preference of $.001 per share. The shares of Preferred Stock have no preferential dividends or redemption rights, and no voting rights except as required by law. As of September 30, 2013, 100,098 shares of the Preferred Stock had been converted into 10,009,800 shares of ARCA common stock. An additional 24,802 shares of Preferred Stock were converted into 2,480,200 shares of common stock between October 1, 2013 and October 31, 2013. | |
Each purchaser in the offering was issued a warrant to purchase 50 shares of the Company’s common stock for each share of Preferred Stock purchased. The warrants have an exercise price of $1.60 per share, will expire on the five year anniversary of the date of issuance, and were exercisable immediately upon issuance, provided that the holder will be prohibited from exercising the warrants if, as a result of such exercise, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. | |
The securities were sold pursuant to a placement agreement and have been registered under the Securities Act of 1933 pursuant to the Company’s Registration Statement on Form S-1, as amended (No.333-187508), which was declared effective by the Securities and Exchange Commission on May 29, 2013, and the Preferred Stock and Warrants were offered and sold pursuant to a prospectus dated May 30, 2013. | |
In connection with the Preferred Stock financing, the Company recorded a non-cash dividend of approximately $2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature. Typically, such a deemed dividend would be represented as a reduction in a company’s retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers. However, since ARCA has an accumulated deficit, the deemed dividend is recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers, which are combined in the Company’s statement of stockholders’ equity. | |
Warrants | |
As of September 30, 2013, warrants to purchase approximately 8.2 million shares of common stock were outstanding at exercise prices ranging from $1.60 to $116.89, with a weighted average exercise price per share of $2.53. These warrants, which were granted as part of various financing and business agreements, expire at various times between October 2013 and January 2020. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model. |
Sharebased_Compensation
Share-based Compensation | 21 Months Ended | |||||||||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||||||||
Share-based Compensation | ' | |||||||||||||||||||||||||||||
(8) Share-based Compensation | ||||||||||||||||||||||||||||||
For the three and nine month periods ended September 30, 2013 and 2012 and for the period from Inception through September 30, 2013, the Company recognized the following non-cash, share-based compensation expense in the consolidated statement of operations (in thousands): | ||||||||||||||||||||||||||||||
Three Months | Nine Months | Period from | ||||||||||||||||||||||||||||
Ended September 30, | Ended September 30, | December 17, | ||||||||||||||||||||||||||||
2001 (date of | ||||||||||||||||||||||||||||||
inception) to | ||||||||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | September 30, 2013 | ||||||||||||||||||||||||||
Research and Development | $ | 7 | $ | 25 | $ | 36 | $ | 76 | $ | 626 | ||||||||||||||||||||
Selling, General and Administrative | 42 | 49 | 89 | 167 | 1,700 | |||||||||||||||||||||||||
Restructuring Expense | — | — | — | — | 387 | |||||||||||||||||||||||||
Total | $ | 49 | $ | 74 | $ | 125 | $ | 243 | $ | 2,713 | ||||||||||||||||||||
Stock option transactions for the nine month period ended September 30, 2013 under all plans are as follows: | ||||||||||||||||||||||||||||||
# of Options | Weighted | Weighted | ||||||||||||||||||||||||||||
Average | Average | |||||||||||||||||||||||||||||
Exercise Price | Remaining | |||||||||||||||||||||||||||||
Contractual | ||||||||||||||||||||||||||||||
Term | ||||||||||||||||||||||||||||||
(in years) | ||||||||||||||||||||||||||||||
Options outstanding at December 31, 2012 | 144,019 | $ | 18.28 | 4.91 | ||||||||||||||||||||||||||
Changes during the period: | ||||||||||||||||||||||||||||||
Granted | 731,535 | 1.38 | ||||||||||||||||||||||||||||
Exercised | — | — | ||||||||||||||||||||||||||||
Forfeited, cancelled or expired | (39,113 | ) | 11.07 | |||||||||||||||||||||||||||
Options outstanding at September 30, 2013 | 836,441 | $ | 3.84 | 9.39 | ||||||||||||||||||||||||||
Options exercisable at September 30, 2013 | 115,435 | $ | 18.08 | 6.12 | ||||||||||||||||||||||||||
Options vested and expected to vest | 721,216 | $ | 4.20 | 9.31 | ||||||||||||||||||||||||||
Income_Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2013 | |
Income Taxes | ' |
(9) Income Taxes | |
In accordance with United States Generally Accepted Accounting Principles, a valuation allowance should be provided if it is more likely than not that some or all of the Company’s deferred tax assets will not be realized. The Company’s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. The Company believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has no reserve for uncertain tax positions. |
The_Company_and_Summary_of_Sig1
The Company and Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2013 | |
Description of Business | ' |
Description of Business | |
ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado and is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, Gencaro™ (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator that ARCA plans to evaluate in a new clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro’s pharmacology and may predict patient response to the drug. | |
The Company plans to test this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, suggest that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is planned as a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients recently diagnosed with persistent AF and having beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF or all-cause mortality. | |
ARCA has created an adaptive design for GENETIC-AF which it plans to initiate with a Phase 2B study in approximately 200 HFREF patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze selected data from the Phase 2B portion of the trial and recommend whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of selected trial data after 200 patients have been enrolled and have completed 24 weeks of follow-up, the period for measuring the trial’s primary end-point. The interim analysis will focus on available data regarding AF event rates, AF burden, and safety. Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and that the data indicates potential for achieving statistical significance for the Phase 3 endpoint, then the DSMB may recommend the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial’s clinical steering committee and the DSMB, will make the final determination on the trial’s development steps. The Company believes the Phase 2B portion of the study would take approximately two and one-half years to complete from the time the first patient is enrolled until the planned DSMB interim analysis of data from the initial 200 patients. | |
The Company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing, which the Company believes may provide market exclusivity for these uses of Gencaro into at least 2026 in the U.S. and into 2025 in Europe. In addition, the Company believes that if Gencaro is approved, a Gencaro patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for Gencaro into 2029 or 2030 in the U.S. and Europe. | |
To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional funding through public or private equity transactions or a strategic combination or partnership. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. | |
Development Stage Risks, Liquidity and Going Concern | ' |
Development Stage Risks, Liquidity and Going Concern | |
The Company is in the development stage and devotes substantially all of its efforts towards obtaining regulatory approval for Gencaro and raising capital necessary to fund its operations. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of common and preferred stock, as well as through the business combination with Nuvelo, Inc, or Nuvelo. | |
Since ARCA was founded on December 17, 2001, or Inception, the Company has incurred substantial losses and negative cash flows from operations. Since Inception, the Company incurred a loss from operations of $103.1 million and had negative cash flows from operations of $100.8 million. | |
To support the continued development of Gencaro, the Company completed a public equity offering in June 2013 to initiate the Phase 2B/3 GENETIC-AF trial and fund ongoing operations. In light of the substantial additional time and costs associated with the development of Gencaro, the Company will need to raise a significant amount of capital on acceptable terms to finance the completion of GENETIC-AF and the Company’s ongoing operations. The Company currently believes its cash and cash equivalents balance as of September 30, 2013 will be sufficient to fund its operations through at least 2014. However, changing circumstances may cause the Company to consume capital significantly faster or slower than is currently anticipated. These estimates are based upon assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than currently projected. | |
The Company’s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: | |
the costs and timing for the planned GENETIC-AF clinical trial ; | |
the market price of the Company’s stock and the availability and cost of additional equity or debt capital; | |
the Company’s ability to retain the listing of its common stock on the Nasdaq Capital Market; | |
general economic and industry conditions affecting the availability and cost of capital; | |
the Company’s ability to control costs associated with its operations; | |
the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and | |
the terms and conditions of the Company’s existing collaborative and licensing agreements. | |
The sale of additional equity or convertible debt securities would likely result in additional dilution to the Company’s existing stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company’s capital stock and could contain covenants that would restrict the Company’s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. | |
Reverse Stock Split | ' |
Reverse Stock Split | |
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. | |
Basis of Presentation | ' |
Basis of Presentation | |
The accompanying unaudited consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. The results of operations for the nine months ended September 30, 2013 are not necessarily indicative of results expected for the full year ending December 31, 2013. The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing Gencaro, and raising capital. Accordingly, the Company continues to be considered in the development stage at September 30, 2013. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, as amended. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values. | |
Concentrations of Credit Risk | ' |
Concentrations of Credit Risk | |
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. | |
Accrued Expenses | ' |
Accrued Expenses | |
As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company’s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. |
Loss_Per_Share_Tables
Loss Per Share (Tables) | 9 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Summary of Basic and Diluted Loss Per Share | ' | ||||||||||||||||||||
A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: | |||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
(In thousands, except shares and per share data) | 2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Net loss | $ | (1,723 | ) | $ | (927 | ) | $ | (3,993 | ) | $ | (3,480 | ) | |||||||||
Less: Series A Preferred Stock deemed dividend | — | — | (2,026 | ) | — | ||||||||||||||||
Net loss available to common shareholders | $ | (1,723 | ) | $ | (927 | ) | $ | (6,019 | ) | $ | (3,480 | ) | |||||||||
Weighted average shares of common stock outstanding | 10,835,299 | 2,286,519 | 6,302,611 | 2,116,462 | |||||||||||||||||
Less: Weighted-average shares of unvested common stock | (2,783 | ) | (2,783 | ) | (2,783 | ) | (2,783 | ) | |||||||||||||
Total weighted-average shares used in computing net loss per share attributed to common stockholders | 10,832,516 | 2,283,736 | 6,299,828 | 2,113,679 | |||||||||||||||||
Basic and diluted loss per share | $ | (0.16 | ) | $ | (.41 | ) | $ | (0.96 | ) | $ | (1.65 | ) | |||||||||
Property_and_Equipment_Tables
Property and Equipment (Tables) | 9 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Summary of Property and Equipment | ' | ||||||||||||
Property and equipment consist of the following (in thousands): | |||||||||||||
Estimated Life | September 30, | December 31, | |||||||||||
2013 | 2012 | ||||||||||||
Computer equipment | 3 years | $ | 97 | $ | 104 | ||||||||
Lab equipment | 5 years | 142 | 142 | ||||||||||
Furniture and fixtures | 5 years | 86 | 93 | ||||||||||
Computer software | 3 years | 176 | 176 | ||||||||||
Leasehold improvements | Lesser of useful life or life of the lease | 8 | 18 | ||||||||||
509 | 533 | ||||||||||||
Less accumulated depreciation and amortization | (482 | ) | (510 | ) | |||||||||
$ | 27 | $ | 23 | ||||||||||
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 9 Months Ended | ||||
Sep. 30, 2013 | |||||
Future Minimum Lease Payments | ' | ||||
Effective August, 1, 2013 the Company entered into a lease agreement for approximately 5,300 square feet of office facilities in Westminster, Colorado that has served as the Company’s primary business office since October 1, 2013. Below is a summary of the future minimum lease payments committed for the Company’s facility in Westminster, Colorado as of September 30, 2013: | |||||
2013 | $ | 19,000 | |||
2014 | 78,000 | ||||
2015 | 81,000 | ||||
2016 | 62,000 | ||||
Total future minimum lease payments | $ | 240,000 | |||
Sharebased_Compensation_Tables
Share-based Compensation (Tables) | 9 Months Ended | |||||||||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||||||||
Non-cash, Share-Based Compensation Expense | ' | |||||||||||||||||||||||||||||
For the three and nine month periods ended September 30, 2013 and 2012 and for the period from Inception through September 30, 2013, the Company recognized the following non-cash, share-based compensation expense in the consolidated statement of operations (in thousands): | ||||||||||||||||||||||||||||||
Three Months | Nine Months | Period from | ||||||||||||||||||||||||||||
Ended September 30, | Ended September 30, | December 17, | ||||||||||||||||||||||||||||
2001 (date of | ||||||||||||||||||||||||||||||
inception) to | ||||||||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | September 30, 2013 | ||||||||||||||||||||||||||
Research and Development | $ | 7 | $ | 25 | $ | 36 | $ | 76 | $ | 626 | ||||||||||||||||||||
Selling, General and Administrative | 42 | 49 | 89 | 167 | 1,700 | |||||||||||||||||||||||||
Restructuring Expense | — | — | — | — | 387 | |||||||||||||||||||||||||
Total | $ | 49 | $ | 74 | $ | 125 | $ | 243 | $ | 2,713 | ||||||||||||||||||||
Summary of Stock Option Activities | ' | |||||||||||||||||||||||||||||
Stock option transactions for the nine month period ended September 30, 2013 under all plans are as follows: | ||||||||||||||||||||||||||||||
# of Options | Weighted | Weighted | ||||||||||||||||||||||||||||
Average | Average | |||||||||||||||||||||||||||||
Exercise Price | Remaining | |||||||||||||||||||||||||||||
Contractual | ||||||||||||||||||||||||||||||
Term | ||||||||||||||||||||||||||||||
(in years) | ||||||||||||||||||||||||||||||
Options outstanding at December 31, 2012 | 144,019 | $ | 18.28 | 4.91 | ||||||||||||||||||||||||||
Changes during the period: | ||||||||||||||||||||||||||||||
Granted | 731,535 | 1.38 | ||||||||||||||||||||||||||||
Exercised | — | — | ||||||||||||||||||||||||||||
Forfeited, cancelled or expired | (39,113 | ) | 11.07 | |||||||||||||||||||||||||||
Options outstanding at September 30, 2013 | 836,441 | $ | 3.84 | 9.39 | ||||||||||||||||||||||||||
Options exercisable at September 30, 2013 | 115,435 | $ | 18.08 | 6.12 | ||||||||||||||||||||||||||
Options vested and expected to vest | 721,216 | $ | 4.20 | 9.31 | ||||||||||||||||||||||||||
The_Company_and_Summary_of_Sig2
The Company and Summary of Significant Accounting Policies (Details) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 141 Months Ended | ||
Mar. 04, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | |
Patients | ||||||
Company Development Stage and Basis of Presentation (Textual) [Abstract] | ' | ' | ' | ' | ' | ' |
Anticipated time to start AF Trial | ' | ' | ' | '168 days | ' | ' |
Number of patients company plans to enroll | ' | ' | ' | 200 | ' | ' |
Number of years to complete the study | ' | ' | ' | '2 years 6 months | ' | ' |
Reverse stock split | '1-for-6 reverse split | ' | ' | ' | ' | ' |
Loss from operations | ' | ($1,725,000) | ($928,000) | ($3,993,000) | ($3,480,000) | ($103,136,000) |
Cash flows from operations | ' | ' | ' | -3,416,000 | -3,408,000 | -100,837,000 |
Revenue generated by the company | ' | ' | ' | ' | ' | $0 |
Phase 3 heart failure (HF) trial of Gencaro | ' | ' | ' | ' | ' | ' |
Company Development Stage and Basis of Presentation (Textual) [Abstract] | ' | ' | ' | ' | ' | ' |
Number of patients | ' | ' | ' | 2,708 | ' | ' |
Number of patients company plans to enroll | ' | ' | ' | 420 | ' | ' |
Loss_Per_Share_Details
Loss Per Share (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 24 Months Ended | 141 Months Ended | ||||||||||
In Thousands, except Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Dec. 31, 2005 | Dec. 31, 2004 | Dec. 31, 2003 | Sep. 30, 2013 |
Summary of basic and diluted loss per share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss | ($1,723) | ($927) | ($3,993) | ($3,480) | ($4,320) | ($5,364) | ($8,420) | ($9,138) | ($19,431) | ($13,994) | ($5,241) | ($1,459) | ($511) | ($116) | ($71,987) |
Less: Deemed preferred stock dividend | ' | ' | -2,026 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,807 |
Net loss attributable to common stockholders | ($1,723) | ($927) | ($6,019) | ($3,480) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($75,039) |
Weighted average shares of common stock outstanding | 10,835,299 | 2,286,519 | 6,302,611 | 2,116,462 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Less: Weighted-average shares of unvested common stock | -2,783 | -2,783 | -2,783 | -2,783 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total weighted-average shares used in computing net loss per share attributed to common stockholders | 10,832,516 | 2,283,736 | 6,299,828 | 2,113,679 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basic and diluted loss per share | ($0.16) | ($0.41) | ($0.96) | ($1.65) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Loss_Per_Share_Details_Textual
Loss Per Share (Details Textual) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Earnings (Loss) Per Share (Textual) [Abstract] | ' | ' | ' | ' |
Weighted average shares of common stock, Diluted | 13.1 | 0.8 | 6.7 | 0.7 |
Merger_with_Nuvelo_Inc_on_Janu1
Merger with Nuvelo, Inc. on January 27, 2009 (Details) (USD $) | 1 Months Ended | 141 Months Ended |
Jan. 27, 2009 | Sep. 30, 2013 | |
Merger with Nuvelo, Inc. On January 27, 2009 (Textual) [Abstract] | ' | ' |
Estimated total acquisition consideration | $11,900,000 | ' |
Net assets acquired in the Merger | 37,200,000 | ' |
Net assets acquired, including cash, cash equivalents and marketable securities | 45,500,000 | ' |
Gain on bargain purchase | $25,300,000 | $25,282,000 |
Fair_Value_Disclosures_Details
Fair Value Disclosures (Details) (USD $) | 3 Months Ended | 9 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2013 |
Fair Value Disclosures (Additional Textual) [Abstract] | ' | ' |
Cash equivalents consisting of money market funds with maturities | '90 days | '90 days |
Transfers of assets between fair value hierarchy levels | $0 | $0 |
Money Market Funds | ' | ' |
Fair Value Disclosures (Textual) [Abstract] | ' | ' |
Cash equivalents consisting of money market funds | $18.60 | $18.60 |
Property_and_Equipment_Details
Property and Equipment (Details) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Dec. 31, 2012 |
Components of Property and equipment | ' | ' |
Property and Equipment, Gross | $509 | $533 |
Less accumulated depreciation and amortization | -482 | -510 |
Property and equipment, net | 27 | 23 |
Computer Equipment | ' | ' |
Components of Property and equipment | ' | ' |
Estimated Life | '3 years | ' |
Property and Equipment, Gross | 97 | 104 |
Lab equipment | ' | ' |
Components of Property and equipment | ' | ' |
Estimated Life | '5 years | ' |
Property and Equipment, Gross | 142 | 142 |
Furniture and Fixtures | ' | ' |
Components of Property and equipment | ' | ' |
Estimated Life | '5 years | ' |
Property and Equipment, Gross | 86 | 93 |
Computer software | ' | ' |
Components of Property and equipment | ' | ' |
Estimated Life | '3 years | ' |
Property and Equipment, Gross | 176 | 176 |
Leasehold Improvements | ' | ' |
Components of Property and equipment | ' | ' |
Leasehold improvements | 'Lesser of useful life or life of the lease | ' |
Property and Equipment, Gross | $8 | $18 |
Property_and_Equipment_Details1
Property and Equipment (Details Textual) (USD $) | 9 Months Ended | 141 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | |
Property and Equipment (Textual) [Abstract] | ' | ' | ' |
Depreciation and amortization expense | $24,000 | $34,000 | $1,800,000 |
Commitments_and_Contingencies_1
Commitments and Contingencies (Details Textual) (USD $) | 0 Months Ended | 1 Months Ended | 9 Months Ended | 141 Months Ended | |||
Feb. 08, 2008 | Jul. 31, 2008 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Jun. 30, 2011 | Aug. 01, 2013 | |
sqft | sqft | Subsequent Event | |||||
sqft | |||||||
Commitments and Contingencies (Textual) [Abstract] | ' | ' | ' | ' | ' | ' | ' |
Area of office facilities taken on lease | 15,000 | ' | ' | ' | ' | 4,500 | 5,300 |
Lease term | '5 years | ' | ' | ' | ' | ' | ' |
Lease expiry period | ' | ' | '2013-09 | ' | ' | ' | ' |
Rent expense | ' | ' | $44,000 | $36,000 | $559,000 | ' | ' |
Milestone payment | ' | 500,000 | ' | ' | ' | ' | ' |
Expected milestone payments upon approval | ' | 8,000,000 | ' | ' | ' | ' | ' |
Another expected milestone payments upon approval | ' | $5,000,000 | ' | ' | ' | ' | ' |
Minimum percentage of royalty obligation | ' | 12.50% | ' | ' | ' | ' | ' |
Maximum percentage of royalty obligation | ' | 25.00% | ' | ' | ' | ' | ' |
Product sales levels royalty | ' | 5.00% | ' | ' | ' | ' | ' |
Minimum percentage of range of royalties that can be buy down | ' | 12.50% | ' | ' | ' | ' | ' |
Maximum percentage of range of royalties that can be buy down | ' | 17.00% | ' | ' | ' | ' | ' |
Milestone payment due period | ' | '6 months | ' | ' | ' | ' | ' |
Equity_Financings_and_Warrants1
Equity Financings and Warrants (Details) (USD $) | 9 Months Ended |
Sep. 30, 2013 | |
Equity financings and warrants (Textual) [Abstract] | ' |
Number of warrants outstanding | $8,200,000 |
Weighted Average | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Warrant price per share | 2.53 |
Minimum | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Warrant price per share | 1.6 |
Maximum | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Warrant price per share | 116.89 |
PIPE Transaction | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Equity Subscription Date | 22-Jan-13 |
Shares issued | 356,430 |
Additional shares that may be purchased | 249,501 |
Aggregate gross proceeds | 1,000,000 |
Net proceeds from the issuance of stock | 805,000 |
Equity issuance close date | 25-Jan-13 |
Shares of common stock purchasable for each warrant sold | 0.7 |
Equity issuance per share amount | $2.81 |
Expiration period of warrants exercise rights | '7 years |
Warrant price per share | 2.28 |
Warrants exercise price as a percentage of closing bid price | 100.00% |
Closing bid price date | 22-Jan-13 |
Effective date of registration statement for resale of shares sold in private placements | 14-Feb-13 |
Registered Direct Offering | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Equity Subscription Date | 31-Jan-13 |
Shares issued | 164,636 |
Additional shares that may be purchased | 65,855 |
Aggregate gross proceeds | 730,000 |
Net proceeds from the issuance of stock | 616,000 |
Equity issuance close date | 4-Feb-13 |
Shares of common stock purchasable for each warrant sold | 0.4 |
Equity issuance per share amount | $4.43 |
Expiration period of warrants exercise rights | '5 years |
Warrant price per share | 4.13 |
Closing bid price date | 31-Jan-13 |
Effective date of filing for securities sold in offering | 1-Feb-13 |
Public Offering | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Additional shares that may be purchased | 6,250,000 |
Net proceeds from the issuance of stock | 17,900,000 |
Equity issuance close date | 4-Jun-13 |
Expiration period of warrants exercise rights | '5 years |
Warrant price per share | 1.6 |
Common stock shares issued upon conversion of each share of convertible preferred stock | 100 |
Maximum limit on percentage of ownership in common stock | 9.99% |
Preferred stock liquidation preference per share | $0.00 |
Common Stock, Shares, Issued for Preferred Stock | 50 |
Intrinsic value of embedded beneficial conversion feature | 2,000,000 |
Public Offering | Preferred Stock | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Number of shares of preferred stock converted in to common stock | 100,098 |
Public Offering | Common Stock | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Number of shares of common stock issued in conversion of preferred stock | 10,009,800 |
Public Offering | Series A Convertible Preferred Stock | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Shares issued | 125,000 |
Aggregate gross proceeds | $20,000,000 |
Equity issuance per share amount | $160 |
Public Offering | Stock Converted On October Two Thousand Thirteen | Preferred Stock | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Number of shares of preferred stock converted in to common stock | 24,802 |
Public Offering | Stock Converted On October Two Thousand Thirteen | Common Stock | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Number of shares of common stock issued in conversion of preferred stock | 2,480,200 |
Director And Chief Executive Officer | Public Offering | ' |
Equity financings and warrants (Textual) [Abstract] | ' |
Additional shares that may be purchased | 39,050 |
Preferred Stock Purchased by Officer | 781 |
Commitments_and_Contingencies_2
Commitments and Contingencies (Details) (USD $) | Sep. 30, 2013 |
Disclosure Commitments And Contingencies Details [Line Items] | ' |
2013 | $19,000 |
2014 | 78,000 |
2015 | 81,000 |
2016 | 62,000 |
Total future minimum lease payments | $240,000 |
Sharebased_Compensation_Detail
Share-based Compensation (Details) (USD $) | 3 Months Ended | 9 Months Ended | 141 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 |
Non-cash, share-based compensation expense | ' | ' | ' | ' | ' |
Total expenses | $49 | $74 | $125 | $243 | $2,713 |
Research and Development | ' | ' | ' | ' | ' |
Non-cash, share-based compensation expense | ' | ' | ' | ' | ' |
Total expenses | 7 | 25 | 36 | 76 | 626 |
Selling, General and Administrative | ' | ' | ' | ' | ' |
Non-cash, share-based compensation expense | ' | ' | ' | ' | ' |
Total expenses | 42 | 49 | 89 | 167 | 1,700 |
Restructuring Expense | ' | ' | ' | ' | ' |
Non-cash, share-based compensation expense | ' | ' | ' | ' | ' |
Total expenses | ' | ' | ' | ' | $387 |
Sharebased_Compensation_Detail1
Share-based Compensation (Details 1) (USD $) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2013 | Dec. 31, 2012 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ' | ' |
Options outstanding beginning of period | 144,019 | ' |
Number of Options, Granted | 731,535 | ' |
Issuance of common stock upon exercise of stock options, for cash, shares | ' | ' |
Number of Options Forfeited, cancelled or expired | 39,113 | ' |
Options outstanding end of the period | 836,441 | 144,019 |
Options exercisable, end of period, Number of Options | 115,435 | ' |
Options vested and expected to vest, Number of Options | 721,216 | ' |
Weighted Average exercise Price, Options Outstanding, Beginning of period | $18.28 | ' |
Weighted average exercise price, Granted | $1.38 | ' |
Weighted average exercise price, Exercised | ' | ' |
Weighted average exercise price, Forfeited, cancelled or expired | $11.07 | ' |
Weighted Average exercise Price, Options Outstanding, end of period | $3.84 | $18.28 |
Weighted average exercise price, Options exercisable, end of period | $18.08 | ' |
Weighted Average exercise Price, Options vested and expected to vest, end of period | $4.20 | ' |
Weighted Average Remaining Contractual Term (in years) Options Outstanding | '9 years 4 months 21 days | '4 years 10 months 28 days |
Options exercisable at September 30, 2013, Weighted Average Remaining Contractual Term (in years) | '6 years 1 month 13 days | ' |
Options vested and expected to vest, Weighted Average Remaining Contractual Term (in years) | '9 years 3 months 22 days | ' |
Income_Taxes_Details
Income Taxes (Details) (USD $) | Sep. 30, 2013 |
Income Taxes (Textual) [Abstract] | ' |
Reserve for uncertain tax positions | $0 |